Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2005-05-24
2005-05-24
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093210, C424S192100, C424S212100, C435S006120, C435S320100
Reexamination Certificate
active
06896881
ABSTRACT:
The invention relates to compositions and methods for treating a patient having a tumor in order to reduce tumor size, comprising administering to the patient a replication-competent Paramyxoviridae virus comprising two or more of a) a nucleic acid sequence encoding a heterologous polypeptide, wherein upon administration the heterologous polypeptide is detectable in a biological fluid of the patient, and detection of the heterologous polypeptide is indicative of Paramyxoviridae virus growth in the patient and reduction in tumor size; b) a recombinant F protein, H protein, or M protein of Paramyxoviridae virus that increases fusogenicity of virus with cells; c) a nucleic acid sequence encoding a cytokine; and d) a Paramyxoviridae virus that is specific for cells of the tumor.
REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4500512 (1985-02-01), Barme
patent: 4985244 (1991-01-01), Makino et al.
patent: 5001692 (1991-03-01), Farla et al.
patent: 5137727 (1992-08-01), Eckenhoff
patent: 5175099 (1992-12-01), Wills
patent: 5262359 (1993-11-01), Hierholzer
patent: 5304367 (1994-04-01), Biegon
patent: 5698530 (1997-12-01), Schlom et al.
patent: 5713858 (1998-02-01), Heruth et al.
patent: 5714347 (1998-02-01), Haas et al.
patent: 5731306 (1998-03-01), Flynn et al.
patent: 5738985 (1998-04-01), Miles et al.
patent: 5773222 (1998-06-01), Scott
patent: 5980508 (1999-11-01), Cardamone et al.
patent: 5981481 (1999-11-01), Fearon et al.
patent: 6012034 (2000-01-01), Hamparian et al.
patent: 6022683 (2000-02-01), Poirier
patent: 6026316 (2000-02-01), Kucharczyk et al.
patent: 6054273 (2000-04-01), Housman
patent: 6077519 (2000-06-01), Storkus et al.
patent: 6083751 (2000-07-01), Feldhaus et al.
patent: 6095976 (2000-08-01), Nachtomy et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6632800 (2003-10-01), Russell et al.
patent: 0 700 995 (1996-03-01), None
patent: WO 9712032 (1997-04-01), None
patent: WO 0076450 (2000-12-01), None
Singh et al., Jan. 1999, Journal of General Virology, vol. 80, pp. 101-106.*
Bailly et al., “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates,”J. Virol., 2000, 74:3188-3195.
Schirrmacher et al., “Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus,”Gene Therapy, 1999, 6:63-73.
Tao et al., “Recovery of a Fully Viable Chimeric Human Parainfluenza Virus (PIV) Type 3 in Which the Hemagglutinin-Neuraminidase and Fusion Glycoproteins Have Been Replaced by Those of PIV Type 1,”J. Virol., 1998, 72:2955-2961.
Cathomen et al., “Measles Viruses with Altered Envelope Protein Cytoplasmic Tails Gain Cell Fusion Competence”, (Feb. 1998),Journal of Virology, vol. 72, No. 2, p. 1224-1234.
Kao et al., “C-Peptide Immunochemiluminometric Assay Developed From Two Seemingly Identical Polyclonal Antisera”, (1992)Annals of Clinical and Laboratory Science, vol. 22, No. 5, p. 307 350.
Radecke, et al., “Rescue of Measles viruses from cloned DNA”, (1995),The Embo Journalvol. 14 No. 23, pp. 5773-5784.
Cathomen et al., “A Matrix-less Measles Virus is Infectious and Elicits Extensive Cell Fusion: Consequences for Propagation in the Brain”, (1998),The Embo Journalvol. 17 No. 14 pp. 3899-3908.
Asada, “Treatment of Human Cancer with Mumps Virus”, (1974),Cancer34:1907-1928.
Bennett et al.,Biotechniques, 1998, 24(3):478-482.
Kirn et al.,Molecular Medicine Today, 1996, 2(12):519-527.
Lorence et al.,Journal of the National Cancer Institute, 1994, 86(16):1228-1233.
Sinkovics et al.,Medical Hypotheses, 1995, 44:359-368.
GenBank Accession No. U60282.
Albonico et al., “Febrile infectious childhood diseases in the history of cancer patients and matched controls,”Medical Hypotheses, 1998, 51:315-320.
Alemany et al., “Replicative adenoviruses for cancer therapy,”Nature Biotechnol., 2000, 18:723-727.
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA, 1996, 93:11313-11318.
Arbit et al., “Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2in human brain tumors,”Eur. J. Nucl. Med., 1995, 22:419-426.
Bae et al., “Genomic Differences between the Diabetogenic and Nondiabetogenic Variants of Encephalomyocarditis Virus,”Virology, 1989, 170:282-287.
Bateman et al., “Fusogenic Membrane Glycoproteins—A Novel Class of Cytotoxic Genes with Immunostimulatory Properties,”Gene Therapy, 1999, 6(Suppl. 1):S6, Abstract #24.
Bateman et al., “Fusogenic Membranes Glycoproteins As a Novel Class of Genes for the Local and Immune-mediated Control of Tumor Growth,”Cancer Res., 2000, 60:1492-1497.
Berg et al., “Physiological functions of endosomal proteolysis,”Biochem. J., 1995, 307:313-326.
Bluming and Ziegler, “Regression of Burkitt's Lymphoma in Association with Measles Infection,”Lancet, 1971, pp. 105-106.
Bolt and Pedersent, “The Role of Subtilisin-like Proprotein Convertases for Cleavage of the Measles Virus Fusion Glycoprotein in Different Cell Types,”Virology, 1998, 252:387-398.
Chambers et al., “Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma,”Proc. Natl. Acad. Sci. USA, 1995, 92:1411-1415.
Ch'ien et al., “Fatal Subacute Immunosuppressive Measles Encephalitis (SIME) in Children with Acute Lymphcytic Leukemia—Clinical, Electroencephalographic, and Computerized Tomographic Scan Features,”Clin. Electroencephalogr., 1983, 14(4):214-220.
Cohen et al., “Complete nucleotide sequence of an attenuated hepatitis A virus: Comparison with wild-type virus,”Proc. Natl. Acad. Sci. USA, 1987, 84:2497-2501.
Crawford et al., “Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography,”Eur. J. Nucl. Med., 1997, 24:1470-1478.
Dai et al., “Cloning and characterization of the thyroid iodide transporter,”Nature, 1996, 379:458-460.
de Felipe et al., “Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy,”Gene Ther., 1999, 6:198-208.
Delassus et al., “Genetic Organization of Gibbon Ape Leukemia Virus,”Virology, 1989, 173:205-213.
De Swart et al., “Measles in a Dutch hospital introduced by an immuno-compromised infant from Indonesia infected with a new virus genotype,”Lancet, 2000, 355:201-202.
Duechler et al., “Evolutionary relationships within the human rhinovirus genus: Comparison of serotypes 89, 2, and 14,”Proc. Natl. Acad. Sci. USA, 1987, 84:2605-2609.
Duprex et al., “Observation of Measles Virus Cell-to-Cell Spread in Astrocytoma Cells by Using a Green Fluorescent Protein-Expressing Recombinant Virus,”J. Virol., 1999, 73(11):9568-9575.
Earle et al., “The Complete Nucleotide Sequence of a Bovine Enterovirus,”J. Gen. Virol., 1988, 69:253-263.
Eiselein et al., “Treatment of Transplanted Murine Tumors with an Oncolytic Virus and Cyclophosphamide,”Cancer Res., 1978, 38:3817-3822.
Evermann and Burnstein, “Immune Enhancement of the Tumorigenicity of Hamster Brain Tumor Cells Persistently Infected with Measles Virus,”Int. J. Cancer, 1975, 16:861-869.
Flower et al., “Thyroid imaging using position emission tomography—a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis,”Br. J. Radiol., 1990, 63:325-330.
Flower et al., “Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy,”Eur. J. Nucl. Med., 1
Peng Kah-Whye
Russell Stephen James
Chen Shin-Lin
Fish & Richardson P.C. P.A.
Mayo Foundation for Medical Education and Research
LandOfFree
Therapeutic methods and compositions using viruses of the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and compositions using viruses of the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and compositions using viruses of the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3426754